Reversal of experimental pulmonary hypertension by PDGF inhibition.
By R. Schermuly, E. Dony, H. Ghofrani, S. Pullamsetti, R. Savai, Markus Roth, A. Sydykov, Ying-Ju Lai, N. Weissmann, W. Seeger and 1 more. Journal of Clinical Investigation, 2005
1,109 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine, Rheumatology
View Paper: https://www.semanticscholar.org/paper/366c4d92ac405a5100ddae1dd78cace38a5fd679
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Role of platelet-derived growth factors in physiology and medicine. (2008, positive): “Imatinib was recently shown to reverse experimental hypertension in two animal models of PAH (Schermuly et al. 2005).”
- Molecular pathogenesis of pulmonary arterial hypertension. (2008, background): “tinib (Gleevec) can reverse experimental pulmonary hypertension in rats (57) and may improve outcome in patients with end-stage PAH Dana Point classification of pulmonary hypertension Category 1 (PAH) IPAH Heritable PAH Drugs and toxins Portal hypertension HIV Schistosomiasis Congenital heart diseas”
- Pulmonary arterial hypertension (2013, background): “tors antagonist approved for the treatment of chronic myeloid leukaemia [266].”
- Mechanisms of disease: pulmonary arterial hypertension (2011, background): “42, 59 Hepatocyte growth factor (HGF) signals through c-Met (a tyrosine kinase receptor).”